JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i8.11861ArticleWeight Loss Achieves Menstrual Regularity in an Overweight Polycystic Ovary Syndrome Patient: Integrated Lifestyle-Drug Interventionhttps://artdesignp.com/journal/JCNR/9/8/10.26689/jcnr.v9i8.11861HuangJian,WangGaofa,ZhangYu2025982025-09-08Polycystic ovary syndrome (PCOS) is a lifelong disorder affecting reproductive, metabolic, and psychological health. A healthy lifestyle and effective weight management strategies should underpin the treatment of PCOS. This case report documents the successful management of a Chinese patient with PCOS who was overweight and presented with oligomenorrhea and persistent adiposity. The patient was diagnosed using the Rotterdam criteria. The intervention was a 2-month program involving caloric restriction (1,350 kcal/day whole-food diet), progressive exercise titration (150–180 min/week of aerobic and resistance training), mindfulness practice, and metformin initiation after confirmed insulin resistance (HOMA-IR 3.67) resulted in clinically significant body composition improvements: fat mass was reduced by 5.0 kg, visceral adipose area was reduced by 44.7 cm², skeletal muscle was increased by 1.4 kg, and regular menstrual cycles (32 day interval) were restored following 5% weight loss––consistent with evidence linking this threshold to improved ovarian function. The combination of a structured lifestyle modification program with targeted pharmacotherapy offers a viable clinical approach for metabolic PCOS phenotypes, although further validation is required to ascertain long-term efficacy.

Teede HJ, Tay CT, Laven JJE, et al., 2023, Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 108(10): 2447–2469.

Norman RJ, Dewailly D, Legro RS, et al., 2007, Polycystic Ovary Syndrome. Lancet, 370(9588): 685–697.

Burghen GA, Givens JR, Kitabchi AE, 1980, Correlation of Hyperandrogenism With Hyperinsulinism in Polycystic Ovarian Disease. Journal of Clinical Endocrinology and Metabolism, 50(1): 113–116.

Joham AE, Norman RJ, Stener-Victorin E, et al., 2022, Polycystic Ovary Syndrome. Lancet Diabetes & Endocrinology, 10(9): 668–680.

Gibson-Helm M, Teede H, Dunaif A, et al., 2017, Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 102(2): 604–612.

Kim JY, Tfayli H, Michaliszyn SF, et al., 2016, Distinguishing Characteristics of Metabolically Healthy Versus Metabolically Unhealthy Obese Adolescent Girls With Polycystic Ovary Syndrome. Fertility and Sterility, 105(6): 1603–1611.

Tahapary DL, Pratisthita LB, Fitri NA, et al., 2022, Challenges in the Diagnosis of Insulin Resistance: Focusing on the Role of HOMA-IR and Triglyceride/Glucose Index. Diabetes & Metabolic Syndrome, 16(8): 102581.

Domecq JP, Prutsky G, Mullan RJ, et al., 2013, Adverse Effects of the Common Treatments for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 98(12): 4646–4654.

Harrison CL, Lombard CB, Moran LJ, et al., 2011, Exercise Therapy in Polycystic Ovary Syndrome: A Systematic Review. Human Reproduction Update, 17(2): 171–183.

Moran LJ, Hutchison SK, Norman RJ, et al., 2011, Lifestyle Changes in Women With Polycystic Ovary Syndrome. Cochrane Database of Systematic Reviews, 2011(2): CD007506.

Pasquali R, Gambineri A, Cavazza C, et al., 2011, Heterogeneity in the Responsiveness to Long-Term Lifestyle Intervention and Predictability in Obese Women With Polycystic Ovary Syndrome. European Journal of Endocrinology, 164(1): 53–60.

Sadeghi HM, Adeli I, Calina D, et al., 2022, Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. International Journal of Molecular Sciences, 23(2): 583.

Abraham GS, Divakar PY, Valsala GA, 2021, Association of Metabolic and Inflammatory Markers With Polycystic Ovarian Syndrome (PCOS): An Update. Archives of Gynecology and Obstetrics, 303(3): 631–643.